L'activation de la voie MAPK est la marque de l'activité du glioma de faible grade (pLGG) et de l...
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BMA-MAP2K1-LGG |
|---|---|
| Type | Pertinence thérapeutique |
| État | reviewed 2026-05-04 | pending_clinical_signoff | actionability review required |
| Maladies | DIS-GLIOMA-LOW-GRADE |
| Sources | SRC-EANO-LGG-2024 SRC-NCCN-CNS-2025 |
Faits relatifs à l ' action en justice
| Biomarqueur | BIO-MAP2K1 |
|---|---|
| Variante | MAP2K1 activant la mutation — glioma de faible grade (LGG); BRAF-fusion-négatif, IDH-type sauvage ou IDH mutant; MAPK activation alternative de la voie |
| Maladie | DIS-GLIOMA-LOW-GRADE |
| Niveau ESCAT | IIA |
| Combinaisons recommandées | trametinib 0.025 mg/kg PO QD (pediatric dosing; adult 2 mg/day) — MAP2K1-mutant LGG investigational (TRAM-01 regimen), tovorafenib 420 mg/m² PO QW — BRAF-altered or MAPK-pathway-altered pLGG (FIREFLY-1 eligible), clinical trial enrollment preferred for MAP2K1-mutant LGG (adult or pediatric) |
| Résumé des faits | MAPK pathway activation is the hallmark of pediatric-type low-grade glioma (pLGG) and occurs in ~90% via BRAF-KIAA1549 fusion (~70%), BRAF V600E (~15%), or alternative MAPK alterations including MAP2K1 mutations (~5–10% of BRAF-fusion-negative pLGG). The FIREFLY-1 phase II trial (Kilburn et al., JCO 2024) demonstrated tovorafenib (type II RAF inhibitor) activity in pLGG with MAPK pathway alterations including MAP2K1 mutations: ORR 67% overall; MAP2K1 cohort showed responses. Trametinib (MEK1/2 inhibitor) has demonstrated activity in MAPK-pathway-altered pLGG in the TRAM-01 and FIREFLY-2 trials. In adult LGG, MAP2K1 mutations occur in ~5% (predominantly IDH-wildtype histiocytic NEC); data more limited. For adult IDH-mutant LGG, vorasidenib (IDH1/2 inhibitor) is now standard (INDIGO trial; FDA 2024) — see BMA-IDH-MUTATION-GLIOMA-LOW-GRADE. MAP2K1 mutations in adult LGG without IDH: MEK inhibitors investigational. NCCN CNS 2025: trametinib / tovorafenib Category 2A for MAPK-altered pLGG. |
Notes
ESCAT IIA: MAP2K1 is an actionable MAPK pathway alteration in LGG; MEK inhibitors (trametinib) and RAF inhibitors (tovorafenib) active. BRAF fusion testing (FISH/RNA-seq) should be performed first in pLGG — BRAF-KIAA1549 fusion is the dominant driver and is most robustly treated with RAF inhibitors. MAP2K1 mutation may be identified when BRAF fusion and BRAF V600E are absent. IDH1/2 mutation status is critical for adult LGG: IDH-mutant → vorasidenib; IDH-wildtype + MAP2K1 → MEK inhibitors investigational. Comprehensive molecular testing recommended: IDH1/2, BRAF (fusion + V600E), MAP2K1, CDKN2A/B, 1p/19q codeletion (molecular oligodendroglioma), TERT promoter.
Utilisé par
No reverse references found in the YAML corpus.